Skip Navigation


JAC Advance Access originally published online on January 6, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/2/225    most recent
dkg065v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pulido, F.
Right arrow Articles by Arribas, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pulido, F.
Right arrow Articles by Arribas, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 51, 225-227
© 2003 The British Society for Antimicrobial Chemotherapy

Leading Article

Treatment of advanced HIV infection

Federico Pulido1,* and José R. Arribas2

1 HIV CareUnit, Hospital Universitario 12 de Octubre, Ctra. Andalucia Km 5.4, 28041-Madrid; 2 HIV Care Unit, Internal Medicine Service, Hospital Universitario La Paz, Madrid, Spain

Keywords: efavirenz, protease inhibitors, advanced HIV infection

The first 10% of the full text of this article appears below.

One of the few aspects of HIV infection for which there is universal agreement is that patients with advanced HIV disease, such as those with a history of opportunistic diseases or severe immunological impairment (<100 CD4 lymphocytes/mm3), should receive antiretroviral treatment.1 It is ironic, however, that for this group of patients, who undoubtedly need treatment, there are virtually no controlled data to help clinicians choose the optimal combination of antiretroviral drugs.

Expert recommendations on initial therapy favour the use of regimens that include a single (or boosted) protease inhibitor, or a non-nucleoside reverse transcriptase inhibitor,1,2 without any specific preference based on the immunological status of the patient. Nevertheless, there is widespread belief among clinicians treating HIV infection in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?